A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia
Latest Information Update: 02 Aug 2023
At a glance
- Drugs EG-HPCP-03a (Primary) ; Dexamethasone
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors Evergreen Therapeutics
- 26 Jul 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: No patients COVID-19 morbidity decreased.
- 27 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 27 Jul 2022 Planned primary completion date changed from 1 Oct 2022 to 1 Oct 2023.